BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alere Inc. (ALR) to Launch "Test Target Treat™" Campaign at 9th Annual International Symposium on Antimicrobial Agents and Resistance


3/13/2013 9:54:32 AM

WALTHAM, Mass., March 13, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR) is pleased to announce the launch today of a new campaign, Test Target Treat, at the 9th Annual International Symposium on Antimicrobial Agents and Resistance. The campaign is designed to combat antimicrobial resistance by educating healthcare professionals on the importance of using rapid diagnostics to make more targeted treatment decisions and reduce the inappropriate use of antibiotics.

Antimicrobial resistance (AMR) occurs when microorganisms mutate or acquire resistance genes that enable them to withstand previously effective antimicrobial treatments. It is generally a consequence of the misuse of antibiotics, a rapidly growing global public health concern. In fact, in its 2013 Global Risks Report, the World Economic Forum identified antimicrobial resistance as the greatest threat to human health today and called for incentives to prevent the over-prescription of antibiotics.

"Until now, new antibiotics have been developed to replace older, increasingly ineffective ones. However, human innovation may no longer be outpacing bacterial mutation," stated the report. "[We must find] new ways to stimulate the development of new antibiotics as well as align incentives to prevent their overuse."

The Test Target Treat campaign is intended to reinforce the fact that antibiotics are over-prescribed in 50% of all cases and that treating viral infections with antimicrobial therapies is counterproductive to achieving broad global health. Alere offers a best-in-class rapid diagnostic, the Alere AfinionTM CRP Test, which enables healthcare practitioners to distinguish between respiratory tract infections that require treatment and those that are self-limiting. The company also provides several other diagnostic tools that can help clinicians identify pathogens at the point of care and define an appropriate treatment strategy earlier. These include solutions for Strep A, RSV, Influenza, S. pneumoniae, MRSA and C. difficile. By supplying healthcare providers with a comprehensive set of diagnostic information, Alere hopes to initiate a shift in treatment trends, moving away from the broad over-prescription of antibiotics, which spawned the growing prevalence of serious healthcare-associated infections like MRSA, towards more targeted therapy.

To learn more about Alere's Test Target TreatTM campaign and industry-leading diagnostics, please visit booths #23 and 24. More information is also available on the campaign's website: www.TestTargetTreat.com.

About Alere
By developing new capabilities in near-patient diagnosis, monitoring and health information technology, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology and diabetes. Alere is headquartered in Waltham, Massachusetts. For more information regarding Alere, please visit www.alere.com.

SOURCE Alere Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES